<div class="discover-view disease-state-a study-design-a1-bg view progress-full">

 <!--
<div class="home-btn nav-button loads-page">
	<span>
		<img src="images/incyte-home-btn.png" alt="HOME" title="HOME">
	</span>
</div>
-->
<div class="goback-btn nav-button develop loads-page" data-pagelink="develop" style="display: absolute">
<!--<div class="goback-btn nav-button home-btn" style="display: absolute">-->
	<span>
		<img src="images/ashe-incyte-back-btn.png" alt="Back" title="Back">
	</span>
</div>
	<div class="container-fluid sd-main">
		<h2 class="text-center">Phase 1/2 Study of INCB039110 (JAK1 Inhibitor) in Combination With Ibrutinib in Subjects<br> With Relapsed or Refractory Diffuse Large B-cell Lymphoma

		</h2>
		<div class="col-xs-3 text-center">
			<div class="col-xs-12 study-rationale-nav modal-showx2" href="images/study-rationale/Incyte ASCO 2017 mockup_1200c_Lymphoma_larger-text_v2.jpg">
				<h4 class="absolute-center"><img src="images/people-icon.png"><br>STUDY RATIONALE</h4>
			</div>
			<div class="col-xs-12 bg-blue primary-objectives-nav2">
				<h4 class="absolute-center"><img src="images/ash-incyte-check-blue.png"><br>STUDY OBJECTIVES</h4>
			</div>
			<div class="col-xs-12 study-design-nav2">
				<h4 class="absolute-center"><img src="images/ash-incyte-pencil-blue.png"><br>STUDY DESIGN</h4>
			</div>
			<div class="col-xs-12 criteria-nav2">
				<h4 class="absolute-center"><img src="images/ash-incyte-key-blue.png"><br>KEY INCLUSION &amp;
				<br>EXCLUSION CRITERIA</h4>
			</div>
		</div>

		<!-- PRIMARY OBJECTIVES -->
		<div class="col-xs-9 primary-obj">
			<div class="chevron-container top">
				<img class="chevron-top2" src="images/ashe-incyte-chevron.png">
			</div>

			<div class="sd-main-content2">
				<!-- section 1 -->
				<div class="scroll-wrapper" style="position: relative;">
					<div id="po2">
						<div class="absolute-cen">
						<h3>Phase 2 Primary objective:</h3>
							<ul>
								<li>Evaluate efficacy of itacitinib in combination with ibrutinib in subjects with R/R non–germinal center B-cell DLBCL as demonstrated by ORR</li>
							</ul>
						<br>
						<h3>secondary objectives:</h3>
							<ul>
								<li>Evaluate efficacy in terms of DOR, durable response rate, PFS, and OS</li>
								<li>Evaluate safety and tolerability of treatment combination</li>
							</ul>
					</div>
					</div>
					<!-- section 2 -->
					<div id="sd2">
						<div class="absolute-cen">
						<h3>Study Design</h3>
						<img class="img-responsive" src="images/study-design/39110-206.png">
						<hr>
<!-- 						<p class="tiny-text">The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p> -->
					</div></div>				
					<!-- section 3 -->
					<div id="kiec2" >
						<div class="absolute-cen">
						<h3 >Key inclusion criteria:</h3>
						<ul>
							<li>Age ≥18 years</li>
							<li>R/R histologically documented DLBCL with 1 to 3 prior treatment regimens
								<ul>
									<li>For phase 1, any DLBCL subtype</li>
									<li>For phase 2, ABC or unclassifiable subtypes of DLBCL</li>
								</ul>
							</li>
							<li>Fluorodeoxyglucose-avid disease per the Lugano classification<sup>1</sup></li>
							<li>Eastern Cooperative Oncology Group performance status 0 to 2</li>
						</ul>
						<br>
						<h3>Key exclusion criteria:</h3>
						<ul>
							<li>Transformed DLBCL or DLBCL with coexistent histologies (eg, follicular or mucosa-associated lymphoid tissue lymphoma)</li>
							<li>Primary mediastinal (thymic) large B-cell lymphoma</li>
							<li>Known central nervous system lymphoma (either primary or metastatic)</li>
							<li>Prior autologous or allo-HSCT, or active graft-versus-host disease following allo-HSCT</li>
							<li>Prior or concurrent therapy with a JAK inhibitor, Bruton tyrosine kinase inhibitor, or lenalidomide (phase 2 only) </li>
						</ul>
					</div>
					</div>
				</div>
			</div>

			<div class="liaison-box">
				<h6>To learn if any of your patients might be eligible for participation in these studies or to learn more about becoming an investigator, please speak with one of our Medical Science Liaisons.</h6>
				<p>The efficacy and safety of the investigational compounds discussed have not been established. There is no guarantee that these compounds will become commercially available for the use(s) under investigation.</p>
			</div>

			<div class="chevron-container btm">
				<img class="chevron-btm2" src="images/ashe-incyte-chevron.png">
			</div>
		</div>
	</div>

	<div class="container-fluid text-center absolute-bottom">
		<div class="video-on">
			<div class="col-xs-12">
				<div class="col-xs-offset-11 col-xs-1">
			   		<img class="popup-btn" src="images/ashe-incyte-popup-btn.png">
			    </div>
			</div>
	    </div>
	</div>
	<!--<div class="develop-code">INC-1200e</div> -->
</div>


<div class="pop-up-div studydesign">
	<p>ABC = activated B cell, allo-HSCT = allogeneic hematopoietic stem cell transplantation, DLBCL = diffuse large B-cell lymphoma, DOR = duration of response, JAK = Janus-associated kinase, ORR = objective response rate, OS = overall survival, PFS = progression-free survival, R/R = relapsed or refractory</p>
	<p>1. Cheson BD, Fisher RI, Barrington SF, et al. J Clin Oncol. 2014;32:3059-3068.</p>
</div>